Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 20, 2018

Aries Pharmaceuticals gets FDA nod for Aemcolo to treat Travelers’ Diarrhea

The US Food and Drug Administration (FDA) has approved Aries Pharmaceuticals’ Aemcolo (rifamycin) 194mg delayed-release tablets, a new minimally-absorbed antibiotic that is delivered to the colon, for the treatment of adult patients with Travelers’ Diarrhea caused by non-invasive strains of Escherichia coli.

Aries Pharmaceuticals gets FDA nod for Aemcolo to treat Travelers’ Diarrhea